Skip to main navigation menu Skip to main content Skip to site footer

SECTION B: LIFE SCIENCES

Vol. 5 No. 1 (2013)

Construction of recombinant bacmids with immunogenic genes of FMD virus using the Bac-to-Bac system

DOI
https://doi.org/10.18272/aci.v5i1.119
Submitted
September 29, 2015
Published
2013-04-08

Abstract

The Foot and Mouth disease virus belongs to the Picornavirus family and primarily affects to bovine, ovine, porcine and caprine. The virus is divided in seven serotypes, O, A, C, Sat1, Sat2, Sat3 and Asia1. In Latin America, the most prevalent serotypes are O and A, in Ecuador, serotype O is the most common. Currently, the vaccine in use is that of an inactivated virus that has some disadvantages such as a limited immune response, the need for a cold chain to keep the vaccine functional and the need of a great quantity of virus to manufacture it. An alternative to overcome these inactivated vaccine's problems is the creation of subunit vaccines using a recombinant protein expression system, where only the immunogenic components of the pathogen are used. Therefore, this project's main objective is the application of a Bac-to-Bac system for the construction of recombinant baculovirus with the foot and mouth disease virus’ highly immunogenic capsid genes such as VP1, P1-2A and 3C from serotype O. Recombinant baculoviruses were obtained with the VP1 construct and these will be later transfected in insect cells for the expression and analysis of VP1 as a possible candidate for a subunit vaccine.

viewed = 677 times

References

  1. Strauss, J.; Strauss, G. 2002. "Virus and Human Disease. Plus-Strand RNA and Double-Strand RNA Viruses". Capítulo 3: 57-122.
  2. Rodríguez, L.; Grubman, M. 2009. "Foot and mouth desease virus vaccines". Vaccine, 27: D90-D94.
  3. Brown, F. 1986. "Review Lecture: Foot-And-Mouth Disease - One of the Remaining Great Plagues". Proceedings of the Royal Society of London. Series B, Biological Sciences, 229: 215-226.
  4. Hoy. 2009. "Aftosa dejaría este año más de $25 millones en pérdidas". http://www.hoy.com.ec/noticias-ecuador/aftosa-dejaria-este-ano-mas-de-25-millones-en-perdidas-353857.html.
  5. Sáiz, M.; Nuñez, J.; Jimenez-Clavero, M.; Baranowski, E.; Sobrino, F. 2002. "Foot and mouth desease virus: biology and prospects for disease control". INIA: Madrid, España.
  6. Van Oers, M. 2006. "Vaccines for viral and Parasitic Diseases Produced with Baculovirus Vectors". Advances in virus research, 68: 193-253.
  7. Malirat, V; Bergmann, I. 2003. "Fiebre Aftosa: Instrumentos moleculares para caracterización viral". Centro Panamericano de Fiebre Aftosa.
  8. McPherson, M.; Moller, S. 2010. "PCR: The Basics from background to bench". Garland Science/BIOS Scientific Publishers.
  9. Li, Z.; Yi, Y.; Yin, X.; Zhang, Z.; Liu, J. 2008. "Expression of Foot-and-Mouth Disease Virus Capsid Proteins in Silkworm-Baculovirus Expression System and Its Utilization as a Subunit Vaccine". Plos One, 3.
  10. Xu, Y; Shen, H.; Zhao, M.; Chen, L.; Li, Y; Liao, M.; Y, L.; Chen, J. 2011. "Adenovirus-vectored shRNAs targeted to the highly conserved regions of VP1 and 2B in tándem inhibits replication of foot-and-mouth disease virus both in vitro and in vivo". Journal of Virological Methods.
  11. Grubman, M. 2005. "Development of novel strategies to control foot-and-mouth disease: Marker vaccines and antivirals". Biologicals, 33: 227-234.